10-Q/A

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 10-Q/A

(Mark One)

þQuarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934  For the Quarter Ended June 30, 2013

¨Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the Transition Period From ____________ to ___________

Commission File Number 1-5620

Safeguard Scientifics, Inc.

(Exact name of registrant as specified in its charter)

Pennsylvania
(State or other jurisdiction of	23-1609753
incorporation or organization)	(I.R.S. Employer ID No.)
435 Devon Park Drive
Building 800
Wayne, PA	19087
(Address of principal executive offices)	(Zip Code)

(610) 293-0600

Registrant’s telephone number, including area code

Indicate by check mark whether the Registrant: (1) has filed all reports required to be filed by Section 13 or 15 (d) of the Securities and Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes  þ    No  ¨

Indicate by check mark whether the Registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the Registrant was required to submit and post such files).

Yes  þ    No  ¨

Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See definitions of “large accelerated filer”, “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer  ¨	Accelerated filer  þ	Non-accelerated filer  ¨	Smaller reporting company  ¨
(Do not check if a smaller reporting company)

Indicate by check mark whether the Registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

Yes  ¨    No  þ

Number of shares outstanding as of July 25, 2013

Common Stock 20,976,963

       

EXPLANATORY NOTE

Safeguard Scientifics, Inc. (the Registrant) is filing this amendment (the Form 10-Q/A) to our Quarterly Report on Form 10-Q for the quarter ended June 30, 2013 (the Form 10-Q), filed with the U.S. Securities and Exchange Commission on July 26, 2013, solely to correct an error on the cover page. The cover page of the Form 10-Q incorrectly stated that the amount of the Registrant’s Common Stock outstanding as of July 25, 2013 was 26,976,963 shares.  The cover page of this Form 10-Q/A correctly states that the number of shares of outstanding Common Stock of the Registrant on July 25, 2013 was 20,976,963. This Form 10-Q/A should be read in conjunction with the original Form 10-Q, which continues to be presented as of the date of the Form 10-Q. Except as specifically noted above, this Form 10-Q/A does not modify or update disclosures in the original Form 10-Q. Accordingly, this Form 10-Q/A does not reflect events occurring after the filing of the Form 10-Q or modify or update any related or other disclosures.

   

 2 

Item 6.  Exhibits

(a) Exhibits.

The following is a list of exhibits required by Item 601 of Regulation S-K to be filed as part of this Report. For exhibits that previously have been filed, the Registrant incorporates those exhibits herein by reference. The exhibit table below includes the Form Type and Filing Date of the previous filing and the location of the exhibit in the previous filing which is being incorporated by reference herein. Documents which are incorporated by reference to filings by parties other than the Registrant are identified in a footnote to this table.

Exhibit Number	Description
31.1 †	Certification of Stephen T. Zarrilli pursuant to Rules 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934.
31.2 †	Certification of Jeffrey B. McGroarty pursuant to Rules 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934.
32.1 ‡	Certification of Stephen T. Zarrilli pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
32.2 ‡	Certification of Jeffrey B. McGroarty pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
101  **	The following materials from Safeguard Scientifics, Inc. Quarterly Report on Form 10-Q for the quarter ended June 30, 2013, formatted in XBRL (eXtensible Business Reporting Language); (i) Consolidated Balance Sheets – June 30, 2013 and December 31, 2012 (unaudited); (ii) Consolidated Statements of Operations (unaudited) – Three and six months ended June 30, 2013 and 2012; (iii) Consolidated Statements of Comprehensive Income (Loss) – Three and six months ended June 30, 2013 and 2012 (unaudited); (iv) Condensed Consolidated Statements of Cash Flows– Six months ended June 30, 2013 and 2012 (unaudited); (v) Consolidated Statement of Changes in Equity – Six months ended June 30, 2013 (unaudited); and (vi) Notes to Consolidated Financial Statements (unaudited).

† Filed herewith

‡ Furnished herewith

** Pursuant to Rule 406T of Regulation S-T, the Interactive Data Files on Exhibit 101 hereto are deemed not filed or part of a registration statement or prospectus for purposes of Sections 11 or 12 of the Securities Act of 1933, as amended, are deemed not filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and otherwise are not subject to liability under those sections.

   

 3 

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	SAFEGUARD SCIENTIFICS, INC.
Date: July 29, 2013	/s/    Stephen T. Zarrilli
	Stephen T. Zarrilli
	President and Chief Executive Officer
Date: July 29, 2013	/s/    Jeffrey B. McGroarty
	Jeffrey B. McGroarty
	Senior Vice President and Chief Financial Officer

 4 

EX-31

Exhibit 31.1

CERTIFICATION

I, Stephen T. Zarrilli, certify that:

1.	I have reviewed this Quarterly Report on Form 10-Q/A of Safeguard Scientifics, Inc.;
2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.	The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
	a.	designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
	b.	designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
	c.	evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
	d.	disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.	The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
	a.	all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
	b.	any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

	SAFEGUARD SCIENTIFICS, INC.
Date: July 29, 2013	/s/ Stephen T. Zarrilli
	Stephen T. Zarrilli
	President and Chief Executive Officer

EX-31

Exhibit 31.2

CERTIFICATION

I, Jeffrey B. McGroarty, certify that:

1.	I have reviewed this Quarterly Report on Form 10-Q/A of Safeguard Scientifics, Inc.;
2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.	The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
	a.	designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
	b.	designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
	c.	evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
	d.	disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.	The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
	a.	all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
	b.	any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

	SAFEGUARD SCIENTIFICS, INC.
Date: July 29, 2013	/s/ Jeffrey B. McGroarty
	Jeffrey B. McGroarty
	Senior Vice President and Chief Financial Officer

EX-32

Exhibit 32.1

Certification Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906

of the Sarbanes-Oxley Act of 2002

In connection with the Quarterly Report of Safeguard Scientifics, Inc. (“Safeguard”) on Form 10-Q/A for the three and six months ended June 30, 2013 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Stephen T. Zarrilli, President and Chief Executive Officer of Safeguard, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

1.	The Report fully complies with the requirements of section 13(a) of the Securities Exchange Act of 1934, (15 U.S.C. 78m(a)); and
2.	The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of Safeguard.

	SAFEGUARD SCIENTIFICS, INC.
Date: July 29, 2013	/s/ Stephen T. Zarrilli
	Stephen T. Zarrilli
	President and Chief Executive Officer

EX-32

Exhibit 32.2

Certification Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906

of the Sarbanes-Oxley Act of 2002

In connection with the Quarterly Report of Safeguard Scientifics, Inc. (“Safeguard”) on Form 10-Q/A for the three and six months ended June 30, 2013 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Jeffrey B. McGroarty, Senior Vice President and Chief Financial Officer of Safeguard, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

1.	The Report fully complies with the requirements of section 13(a) of the Securities Exchange Act of 1934, (15 U.S.C. 78m(a)); and
2.	The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of Safeguard.

	SAFEGUARD SCIENTIFICS, INC.
Date: July 29, 2013	/s/ Jeffrey B. McGroarty
	Jeffrey B. McGroarty
	Senior Vice President and Chief Financial Officer

XML

Commitments and Contingencies

6 Months Ended

Jun. 30, 2013

Commitments and Contingencies

10. Commitments and Contingencies

The Company and its partner companies are involved in various claims and legal actions arising in the ordinary course of business. While in the current opinion of the Company the ultimate disposition of these matters will not have a material adverse effect on the Company’s consolidated financial position or results of operations, no assurance can be given as to the outcome of these actions, and one or more adverse rulings could have a material adverse effect on the Company’s consolidated financial position and results of operations or that of its partner companies. The Company records costs associated with legal fees as such services are rendered.

Not including the Laureate Biopharma, Inc. lease guaranty described below, the Company had outstanding guarantees of $3.8 million at June30, 2013.

The Company has committed capital of approximately $0.1 million to a private equity fund. This commitment is expected to be funded during the next 12 months.

Under certain circumstances, the Company may be required to return a portion or all the distributions it received as a general partner of a private equity fund (“clawback”). The maximum clawback the Company could be required to return due to its general partner interest is approximately $1.3 million, of which $1.0 million was reflected in Accrued expenses and other current liabilities and $0.3 million was reflected in Other long-term liabilities on the Consolidated Balance Sheet at June30, 2013. The Company’s ownership in the fund is 19%. The clawback liability is joint and several; therefore the Company may be required to fund the clawback for other general partners should they default. The Company believes its potential liability due to the possibility of default by other general partners is remote.

In connection with the Company’s May 2008 sale of its equity and debt interests in Acsis, Inc., Alliance Consulting Group Associates, Inc., Laureate Biopharma, Inc., ProModel Corporation and Neuronyx, Inc. (the “Bundle Transaction”), an aggregate of $6.4 million of the gross proceeds of the sale were placed in escrow pending the expiration of a predetermined notification period, subject to possible extension in the event of a claim against the escrowed amounts. On April25, 2009, the purchaser in the Bundle Transaction notified the Company of claims being asserted against the entire escrowed amounts. In April 2013, the case was tried on the merits and the verdict in the case denied the purchaser’s claims against the escrowed funds. The escrow funds were released to the Company in June 2013.

The Company remains guarantor of Laureate Biopharma, Inc.’s Princeton, New Jersey facility lease. Such guarantee may extend through the lease expiration in 2016 under certain circumstances. However, the Company is entitled to indemnification in connection with the continuation of such guaranty. As of June30, 2013, scheduled lease payments to be made by Laureate Biopharma, Inc. over the remaining lease term equaled $4.2 million.

In October 2001, the Company entered into an agreement with its former Chairman and Chief Executive Officer to provide for annual payments of $0.65 million per year and certain health care and other benefits for life. The related current liability of $0.8million was included in Accrued expenses and other current liabilities and the long-term portion of $2.8million was included in Other long-term liabilities on the Consolidated Balance Sheet at June30, 2013.

The Company provided a $6.3 million letter of credit expiring on March19, 2019 to the landlord of CompuCom Systems, Inc.’s Dallas headquarters as required in connection with the sale of CompuCom Systems in 2004.

The Company has agreements with certain employees that provide for severance payments to the employee in the event the employee is terminated without cause or an employee terminates his employment for “good reason.” The maximum aggregate exposure under the agreements was approximately $2.4 million at June30, 2013. During the three months ended June 30, 2013, a Company executive terminated his employment for “good reason.” As a result of the termination, the Company recognized a severance charge of $0.9 million which is recorded in Accrued compensation and benefits on the Consolidated Balance Sheet at June 30, 2013.

XML

CONSOLIDATED STATEMENTS OF OPERATIONS (USD $) In Thousands, except Per Share data, unless otherwise specified	3 Months Ended		6 Months Ended
	Jun. 30, 2013	Jun. 30, 2012	Jun. 30, 2013	Jun. 30, 2012
General and administrative expense	$ 6,715	$ 5,148	$ 12,089	$ 9,891
Operating loss	(6,715)	(5,148)	(12,089)	(9,891)
Other income (loss), net	(2,724)	4,819	(1,967)	7,903
Interest income	790	595	1,524	1,494
Interest expense	(1,074)	(1,456)	(2,143)	(2,908)
Equity loss	(18,400)	(8,947)	(25,387)	(16,395)
Net loss before income taxes	(28,123)	(10,137)	(40,062)	(19,797)
Income tax benefit (expense)	0	0	0	0
Net loss	$ (28,123)	$ (10,137)	$ (40,062)	$ (19,797)
Net loss per share:
Basic	$ (1.33)	$ (0.48)	$ (1.90)	$ (0.95)
Diluted	$ (1.33)	$ (0.48)	$ (1.90)	$ (0.95)
Weighted average shares used in computing basic and diluted loss per share:	21,128	20,927	21,119	20,903

XML

Acquisitions of Ownership Interests in Partner Companies and Funds

6 Months Ended

Jun. 30, 2013

Acquisitions of Ownership Interests in Partner Companies and Funds

3. Acquisitions of Ownership Interests in Partner Companies and Funds

During the six months ended June 30, 2013, the Company funded $2.3 million for participations in loan and equity interests initiated by Penn Mezzanine. Included in this funding were $2.2 million for participation in a loan and $0.1 million for participation in equity of the borrower acquired by Penn Mezzanine.

During the six months ended June 30, 2013, the Company funded an aggregate of $5.3 million of a convertible bridge loan to PixelOptics. The Company previously deployed an aggregate of $31.6 million in PixelOptics. PixelOptics provides electronic corrective eyeglasses designed to substantially reduce or eliminate the visual distortion and other limitations associated with multifocal lenses. The Company accounts for its interest in PixelOptics under the equity method.

In June 2013, the Company deployed an additional $5.3 million into Medivo, Inc. (“Medivo”). The Company had previously acquired an interest in Medivo in November 2011 for $6.3 million. Medivo is a healthcare IT company that connects patients to a nationwide network of physicians, lab service centers and home testing services. The Company accounts for its interest in Medivo under the equity method. With respect to the June 2013 deployment, the difference between the Company’s cost and its interest in the underlying net assets of Medivo was preliminarily allocated to intangible assets and goodwill as reflected in the carrying value in Ownership interests in and advances to partner companies and funds on the Consolidated Balance Sheets.

In June 2013, the Company funded $0.3 million of a convertible bridge loan to Alverix, Inc (“Alverix”). The Company had previously deployed an aggregate of $8.8 million in Alverix. Alverix provides next-generation instrument and connectivity platforms for diagnostic Point-of-Care testing. The Company accounts for its interest in Alverix under the equity method.

In May 2013, the Company funded $0.2 million of a convertible bridge loan to Hoopla Software, Inc. (“Hoopla”). The Company had previously acquired an interest in Hoopla in December 2011 for $1.3 million. Hoopla helps organizations create high performance sales cultures through software-as-a-service solutions that integrate with customer relationship management systems. The Company accounts for its interest in Hoopla under the equity method.

In March 2013, the Company deployed an additional $1.7 million into Lumesis, Inc. (“Lumesis”). The Company had previously acquired an interest in Lumesis in February 2012 for $2.2 million. Lumesis is a financial technology company that is dedicated to delivering timely data and robust analytical tools for the fixed income marketplace. The Company accounts for its interest in Lumesisunder the equity method. The difference between the Company’s cost and its interest in the underlying net assets of Lumesis was allocated to intangible assets and goodwill as reflected in the carrying value in Ownership interests in and advances to partner companies and funds on the Consolidated Balance Sheets.

In February 2013, the Company acquired a 6.5% ownership interest in Clutch Holdings, LLC (“Clutch”) for $0.5 million. Clutch is a mobile commerce platform that unifies applications associated with gifting, loyalty and shopping programs to improve the customer experience. The Company accounts for its interest in Clutch under the cost method.

In February 2013, the Company acquired a 27.6% ownership interest inPneuron, Inc. (“Pneuron”) for $5.0 million. Pneuron helps enterprise companies reduce the time and cost of application development by building solutions across heterogeneous databases and applications. The Company accounts for its ownership interest in Pneuron under the equity method. The difference between the Company’s cost and its interest in the underlying net assets of Pneuron was preliminarily allocated to intangible assets and goodwill as reflected in the carrying value in Ownership interests in and advances to partner companies and funds on the Consolidated Balance Sheets.

In January 2013, the Company acquired a 7.7% interest in Sotera Wireless, Inc. (“Sotera”). The Company deployed $1.3 million into Sotera and acquired additional shares from a previous investor for $1.2 million. Sotera is a medical device company that has developed a wireless patient monitoring platform that is designed to keep clinicians connected to their patients. The Company accounts for its interest in Sotera under the cost method.

XML

Carrying Value of Ownership Interests in and Advances to Partner Companies and Private Equity Funds (Detail) (USD $) In Thousands, unless otherwise specified	Jun. 30, 2013	Dec. 31, 2012
Investments In And Advances To Affiliates [Line Items]
Ownership interests in and advances, to partner companies and funds, fair value	$ 19,363	$ 20,972
Equity method investments	102,711	106,741
Cost method investments	15,514	12,634
Advances to partner companies	5,512	8,292
Ownership interests in and advances to partner companies and funds ($19,363 and $20,972 at fair value at June 30,2013 and December 31,2012, respectively)	143,100	148,639
Loan participations receivable	8,310	7,085
Available-for-sale securities	18	58
Partner companies
Investments In And Advances To Affiliates [Line Items]
Equity method investments	98,997	102,931
Cost method investments	13,030	10,000
Private equity funds
Investments In And Advances To Affiliates [Line Items]
Equity method investments	3,714	3,810
Cost method investments	$ 2,484	$ 2,634

XML

Ownership Interests in and Advances to Partner Companies and Funds (Tables)

6 Months Ended

Jun. 30, 2013

Ownership Interests in and Advances to Partner Companies and Private Equity Funds

The following summarizes the carrying value of the Company’s ownership interests in and advances to partner companies and private equity funds.

	June30,2013		December31,2012
		(Inthousands) (Unaudited)
Fair value	$	19,363	$	20,972
Equity Method:
Partner companies		98,997		102,931
Private equity funds		3,714		3,810
		102,711		106,741
Cost Method:
Partner companies		13,030		10,000
Private equity funds		2,484		2,634
		15,514		12,634
Advances to partner companies		5,512		8,292
	$	143,100	$	148,639
Loan participations receivable	$	8,310	$	7,085
Available-for-sale securities	$	18	$	58

Results of Operations of PixelOptics

The results of PixelOptics are reported on a one quarter lag.

	ThreeMonthsEndedMarch31,
	2013			2012
		(In thousands)
		(Unaudited)
Results of Operations:
Revenue	$	539		$	307
Operating loss	$	(5,855	)	$	(8,721	)
Net loss	$	(7,061	)	$	(9,012	)

XML

Calculations of Net Loss Per Share (Detail) (USD $) In Thousands, except Per Share data, unless otherwise specified	3 Months Ended		6 Months Ended
	Jun. 30, 2013	Jun. 30, 2012	Jun. 30, 2013	Jun. 30, 2012
Basic:
Net loss	$ (28,123)	$ (10,137)	$ (40,062)	$ (19,797)
Weighted average common shares outstanding	21,128	20,927	21,119	20,903
Net loss per share	$ (1.33)	$ (0.48)	$ (1.90)	$ (0.95)
Diluted:
Net loss	$ (28,123)	$ (10,137)	$ (40,062)	$ (19,797)
Weighted average common shares outstanding	21,128	20,927	21,119	20,903
Net loss per share	$ (1.33)	$ (0.48)	$ (1.90)	$ (0.95)

XML

Acquisitions of Ownership Interests in Partner Companies and Funds - Additional Information (Detail) (USD $)	6 Months Ended		1 Months Ended	6 Months Ended	1 Months Ended		6 Months Ended	1 Months Ended			6 Months Ended	1 Months Ended
	Jun. 30, 2013	Jun. 30, 2012	Nov. 30, 2011 Mendivo, Inc.	Jun. 30, 2013 Mendivo, Inc.	May 31, 2013 Hoopla Software, Inc.	Dec. 31, 2011 Hoopla Software, Inc.	Jun. 30, 2013 Penn Mezzanine	Feb. 28, 2013 Clutch Holdings, LLC	Mar. 31, 2013 Lumesis, Inc.	Feb. 29, 2012 Lumesis, Inc.	Jun. 30, 2013 PixelOptics, Inc.	Feb. 28, 2013 Pneuron, Inc.	Jan. 31, 2013 Sotera Wireless, Inc.	Jun. 30, 2013 Alverix
Schedule Of Equity Method Investments [Line Items]
Acquisitions of ownership interests in companies and funds, net of cash acquired	$ 15,131,000	$ 16,190,000	$ 6,300,000	$ 5,300,000				$ 500,000	$ 1,700,000	$ 2,200,000	$ 31,600,000	$ 5,000,000	$ 1,300,000	$ 8,800,000
Fund amount for participations in loan					200,000		2,200,000
Fund amount for participations in equity interests						1,300,000	100,000
Fund amount for participations in loan and equity interests							2,300,000
Ownership interest under equity method, percentage								6.50%				27.60%	7.70%
Convertible bridge loan											5,300,000			300,000
Acquired additional shares from a previous investor													$ 1,200,000

XML

Ownership Interests in and Advances to Partner Companies and Funds - Additional Information (Detail) (USD $) In Millions, unless otherwise specified	3 Months Ended			6 Months Ended	3 Months Ended
	Mar. 31, 2013 Private equity funds	Mar. 31, 2012 Private equity funds	Jun. 30, 2013 Nupathe	Jun. 30, 2013 Nupathe	Jun. 30, 2013 PixelOptics, Inc. Private equity funds	Jun. 30, 2012 PixelOptics, Inc. Private equity funds	Jun. 30, 2013 Penn Mezzanine	Jun. 30, 2012 Penn Mezzanine	Jun. 30, 2013 Penn Mezzanine Impairment charge related to loan participation	Jun. 30, 2012 Penn Mezzanine Impairment charge related to loan participation	Jun. 30, 2012 Penn Mezzanine Equity participation	Jun. 30, 2013 Penn Mezzanine Warrants	Jun. 30, 2012 Penn Mezzanine Warrants
Investment [Line Items]
Recognized impairment charges	$ 0.2	$ 0.4			$ 9.9	$ 3.7	$ 0.3	$ 0.7	$ 0.2	$ 0.2	$ 0.4	$ 0.1	$ 0.1
Recognition of unrealized loss (gain) on mark-to-market of ownership interests			$ 2.4	$ 1.6

XML

Carrying Values of Convertible Senior Debentures (Detail) (USD $) In Thousands, unless otherwise specified	Jun. 30, 2013	Dec. 31, 2012
Debt Instrument [Line Items]
Convertible senior debentures	$ 49,440	$ 48,991
Less: current portion	(470)
Convertible senior debentures-non-current	48,970	48,991
Convertible Senior Debentures due 2018
Debt Instrument [Line Items]
Convertible senior debentures	48,970	48,483
Convertible Senior Debentures due 2014
Debt Instrument [Line Items]
Convertible senior debentures	29	67
Convertible Senior Debentures due 2024
Debt Instrument [Line Items]
Convertible senior debentures	$ 441	$ 441

XML

Operating Segments - Additional Information (Detail) (USD $) In Millions, unless otherwise specified	Jun. 30, 2013	Dec. 31, 2012
Segment Reporting Information [Line Items]
Non-consolidated partner companies	20
Other Items
Segment Reporting Information [Line Items]
Total assets included cash, cash equivalents, cash held in escrow, and marketable securities	$ 180.1	$ 212.5
Penn Mezzanine
Segment Reporting Information [Line Items]
Ownership interest under equity method, percentage	36.00%

XML

Convertible Debentures and Credit Arrangements - Convertible Senior Debentures due 2014 - Additional Information (Detail) (Convertible Senior Debentures due 2014, USD $) In Millions, unless otherwise specified	Jun. 30, 2013	Nov. 30, 2012
Convertible Senior Debentures due 2014
Debt Instrument [Line Items]
Aggregate face value of convertible senior debentures	$ 46.9
Repurchase of Debentures		$ 58.7

XML

Segment Data from Operations (Detail) (USD $) In Thousands, unless otherwise specified	3 Months Ended		6 Months Ended
	Jun. 30, 2013	Jun. 30, 2012	Jun. 30, 2013	Jun. 30, 2012	Dec. 31, 2012
Segment Reporting Information [Line Items]
Operating loss	$ (6,715)	$ (5,148)	$ (12,089)	$ (9,891)
Interest income	790	595	1,524	1,494
Equity loss	(18,400)	(8,947)	(25,387)	(16,395)
Net loss	(28,123)	(10,137)	(40,062)	(19,797)
Segment Assets	336,118		336,118		374,144
Healthcare
Segment Reporting Information [Line Items]
Equity loss	(14,850)	(8,820)	(20,750)	(15,159)
Net loss	(17,275)	(3,270)	(22,340)	(6,180)
Segment Assets	75,154		75,154		83,500
Technology
Segment Reporting Information [Line Items]
Equity loss	(3,399)	(56)	(4,500)	(1,045)
Net loss	(3,399)	(56)	(4,500)	(1,045)
Segment Assets	61,266		61,266		58,753
Penn Mezzanine
Segment Reporting Information [Line Items]
Operating loss	(4)	(2)	(9)	(4)
Interest income	380	277	724	848
Equity loss	(94)	(69)	(164)	(188)
Net loss	(13)	(533)	328	(83)
Segment Assets	13,186		13,186		12,153
Total Segments
Segment Reporting Information [Line Items]
Operating loss	(4)	(2)	(9)	(4)
Interest income	380	277	724	848
Equity loss	(18,343)	(8,945)	(25,414)	(16,392)
Net loss	(20,687)	(3,859)	(26,512)	(7,308)
Segment Assets	149,606		149,606		154,406
Other Items
Segment Reporting Information [Line Items]
Operating loss	(6,711)	(5,146)	(12,080)	(9,887)
Interest income	410	318	800	646
Equity loss	(57)	(2)	27	(3)
Net loss	(7,436)	(6,278)	(13,550)	(12,489)
Segment Assets	$ 186,512		$ 186,512		$ 219,738

XML

Results of Operations of PixelOptics (Detail) (PixelOptics, Inc., USD $) In Thousands, unless otherwise specified	3 Months Ended
	Mar. 31, 2013	Mar. 31, 2012
PixelOptics, Inc.
Results of Operations:
Revenue	$ 539	$ 307
Operating loss	(5,855)	(8,721)
Net loss	$ (7,061)	$ (9,012)

XML

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $) In Thousands, unless otherwise specified	6 Months Ended
	Jun. 30, 2013	Jun. 30, 2012
Cash Flows from Operating Activities:
Net cash used in operating activities	$ (11,540)	$ (9,624)
Cash Flows from Investing Activities:
Proceeds from sales of and distributions from companies and funds	1,403	11,061
Advances and loans to companies	(8,100)	(5,141)
Origination fees on mezzanine loans	42	46
Acquisitions of ownership interests in companies and funds	(15,131)	(16,190)
Increase in marketable securities	(29,913)	(141,997)
Decrease in marketable securities	92,552	133,751
Repayment of advances and loans to companies	928	3,144
Capital expenditures	(21)	(25)
Proceeds from sale of discontinued operations, net	6,434
Net cash provided by (used in) investing activities	48,194	(15,351)
Cash Flows from Financing Activities:
Repurchase of convertible senior debentures	(43)
Issuance of Company common stock, net	92	513
Net cash provided by financing activities	49	513
Net Increase (Decrease) in Cash and Cash Equivalents	36,703	(24,462)
Cash and Cash Equivalents at beginning of period	66,029	83,187
Cash and Cash Equivalents at end of period	$ 102,732	$ 58,725

XML

General

6 Months Ended

Jun. 30, 2013

General

1. General

The accompanying unaudited interim Consolidated Financial Statements of Safeguard Scientifics, Inc. (“Safeguard” or the “Company”) were prepared in accordance with accounting principles generally accepted in the United States of America and the interim financial statement rules and regulations of the SEC. In the opinion of management, these statements include all adjustments (consisting only of normal recurring adjustments) necessary for a fair presentation of the Consolidated Financial Statements. The interim operating results are not necessarily indicative of the results for a full year or for any interim period. Certain information and note disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted pursuant to such rules and regulations relating to interim financial statements. The Consolidated Financial Statements included in this Form 10-Q should be read in conjunction with Management’s Discussion and Analysis of Financial Condition and Results of Operations included elsewhere in this Form 10-Q and with the Company’s Consolidated Financial Statements and Notes thereto included in the Company’s 2012 Annual Report on Form 10-K.

XML

Fair Value Measurements

6 Months Ended

Jun. 30, 2013

Fair Value Measurements

4. Fair Value Measurements

The Company categorizes its financial instruments into a three-level fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The fair value hierarchy gives the highest priority to quoted prices in active markets for identical assets or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3). If the inputs used to measure fair value fall within different levels of the hierarchy, the category level is based on the lowest priority level input that is significant to the fair value measurement of the instrument. Financial assets recorded at fair value on the Company’s Consolidated Balance Sheets are categorized as follows:

Level1—Observable inputs that reflect quoted prices (unadjusted) for identical assets or liabilities in active markets.

Level2—Include other inputs that are directly or indirectly observable in the marketplace.

Level3—Unobservable inputs which are supported by little or no market activity.

The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value.

The following table provides the carrying value and fair value of certain financial assets and liabilities of the Company measured at fair value on a recurring basis as of June30, 2013 and December31, 2012:

	Carrying Value		FairValueMeasurementatJune30,2013
			Level1		Level2			Level3
		(In thousands)
		(Unaudited)
Cash and cash equivalents	$	102,732	$	102,732		$	—		$	—
Cash held in escrow		—		—			—			—
Restricted marketable securities		6		6			—			—
Ownership interest in common stock of NuPathe		15,791		15,791			—			—
Ownership interest in warrants and options of NuPathe		3,572		—			—			3,572
Available-for-sale securities		18		18			—			—
Warrant participations		417		—			—			417
Marketable securities—held-to-maturity:
Commercial paper	$	19,237	$	19,237		$	—		$	—
U.S. Treasury Bills		18,180		18,180			—			—
Government agency bonds		22,166		22,166			—			—
Certificates of deposit		17,794		17,794			—			—
Total marketable securities…………………………………………………	$	77,377	$	77,377		$	—		$	—

	Carrying Value		Fair Value Measurement atDecember 31, 2012
			Level 1		Level 2			Level 3
		(In thousands)
		(Unaudited)
Cash and cash equivalents	$	66,029	$	66,029		$	—		$	—
Cash held in escrow		6,434		6,434			—			—
Restricted marketable securities		10		10			—			—
Ownership interest in common stock of NuPathe		8,897		8,897			—			—
Ownership interest in preferred stock, warrants and options of NuPathe		12,075		—			—			12,075
Available-for-sale securities		58		58			—			—
Warrant participations		423		—			—			423
Marketable securities—held-to-maturity:
Commercial paper	$	50,932	$	50,932		$	—		$	—
U.S. Treasury Bills		21,352		21,352			—			—
Government agency bonds		45,909		45,909			—			—
Certificates of deposit		21,823		21,823			—			—
Total marketable securities…………………………………………………	$	140,016	$	140,016		$	—		$	—

As of June30, 2013, $70.2 million of marketable securities had contractual maturities which were less than one year and $7.2 million of marketable securities had contractual maturities greater than one year. Held-to-maturity securities are carried at amortized cost, which, due to the short-term maturity of these instruments, approximates fair value using quoted prices in active markets for identical assets or liabilities defined as Level 1 inputs under the fair value hierarchy.

The Company recorded an impairment charge of $9.9 million related to PixelOptics in the three months ended June 30, 2013 measured as the amount by which PixelOptics’ carrying value exceeded its estimated fair value.  The fair market value of the Company’s equity ownership in PixelOptics was determined to be $3.3 million based on Level 3 inputs as defined above.  The inputs and valuation techniques used included primarily an evaluation of discounted cash flows for PixelOptics.

The Company’s Penn Mezzanine warrant participations are carried at fair value. The value of the Company’s holdings in warrant participations is measured by reference to Level 3 inputs. The inputs and valuation techniques used include discounted cash flows and valuation of comparable public companies.  The Company recorded an impairment charge of $0.3 million related to its Penn Mezzanine debt and equity participations in the three months ended June 30, 2013 measured as the amount by which the carrying value of the Company’s participation in the debt, equity and warrant interests acquired by Penn Mezzanine exceeded their estimated fair values.

The Company’s ownership interests in NuPathe are accounted for at fair value. In February 2013, the Company converted its 2,500 shares of preferred stock units, acquired in October 2012, into 2.5million shares of common stock in NuPathe. The preferred stock units had been valued using Level 3 inputs. The fair value of the Company’s ownership interest in NuPathe’s common stock was measured using quoted market prices for NuPathe’s common stock as traded on the NASDAQ Capital Market, which is considered a Level 1 input under the valuation hierarchy. The fair value of the Company’s ownership interest in NuPathe’s warrants and options was measured using a Black-Scholes option pricing model, which is based on Level 3 inputs as defined above.

XML

Ownership Interests in and Advances to Partner Companies and Funds

6 Months Ended

Jun. 30, 2013

Ownership Interests in and Advances to Partner Companies and Funds

2. Ownership Interests in and Advances to Partner Companies and Funds

The following summarizes the carrying value of the Company’s ownership interests in and advances to partner companies and private equity funds.

	June30,2013		December31,2012
		(Inthousands) (Unaudited)
Fair value	$	19,363	$	20,972
Equity Method:
Partner companies		98,997		102,931
Private equity funds		3,714		3,810
		102,711		106,741
Cost Method:
Partner companies		13,030		10,000
Private equity funds		2,484		2,634
		15,514		12,634
Advances to partner companies		5,512		8,292
	$	143,100	$	148,639
Loan participations receivable	$	8,310	$	7,085
Available-for-sale securities	$	18	$	58

The Company recognized impairment charges of $9.9 million and $3.7 million related to PixelOptics Inc. (“PixelOptics”) in the three months ended June30, 2013 and 2012, respectively, which are reflected in Equity loss in the Consolidated Statements of Operations. The impairment in 2013 was based on the decision of PixelOptics to seek additional capital from independent sources as well as the Company’s decision to deploy no substantial additional capital in PixelOptics.  The impairment in 2012 was based upon launch delays and related supply chain issues, as well as the pricing of a transaction between other institutional shareholders in PixelOptics.

The Company recorded impairment charges of $0.3 million and $0.7 million related to its Penn Mezzanine debt and equity participations in the three months ended June30, 2013 and 2012, respectively, which are reflected in Other income (loss), net in the Consolidated Statements of Operations. In the three months ended June 30, 2013, the charge included $0.2 million related to loan participations and $0.1 million representing an adjustment to the fair value of the Company’s participation in warrants.  In the three months ended June 30, 2012, the charge included $0.2 million related to loan participations, $0.4 million related to equity participations and $0.1 million representing an adjustment to the fair value of the Company’s participation in warrants.

The Company recognized impairment charges of $0.2 million and $0.4 million related to its interest in a legacy private equity fund in the first quarter of 2013 and 2012, respectively, which are reflected in Other income (loss), net in the Consolidated Statements of Operations.

For the three and six months ended June30, 2013, the Company recognized an unrealized loss of $2.4 million and $1.6 million, respectively, on the mark-to-market of its holdings in NuPathe, Inc. (“NuPathe”), which is included in Other income (loss), net in the Consolidated Statements of Operations.

The following unaudited summarized results of operations for the three months ended March31, 2013 and 2012 for PixelOptics have been compiled from the unaudited financial statements of PixelOptics.

The results of PixelOptics are reported on a one quarter lag.

	ThreeMonthsEndedMarch31,
	2013			2012
		(In thousands)
		(Unaudited)
Results of Operations:
Revenue	$	539		$	307
Operating loss	$	(5,855	)	$	(8,721	)
Net loss	$	(7,061	)	$	(9,012	)

XML

Active Partner Companies by Segment (Detail)	Jan. 31, 2013 Sotera Wireless, Inc.	Feb. 28, 2013 Pneuron, Inc.	Jun. 30, 2013 Healthcare AdvantEdge Healthcare Solutions, Inc.	Jun. 30, 2013 Healthcare Alverix, Inc.	Jun. 30, 2013 Healthcare Crescendo Bioscience, Inc.	Jun. 30, 2013 Healthcare Good Start Genetics, Inc.	Jun. 30, 2013 Healthcare Medivo, Inc.	Jun. 30, 2013 Healthcare NovaSom, Inc.	Jun. 30, 2013 Healthcare NuPathe		Jun. 30, 2013 Healthcare PixelOptics, Inc.	Jun. 30, 2013 Healthcare Putney, Inc.	Jun. 30, 2013 Healthcare Sotera Wireless, Inc.	Jun. 30, 2013 Technology AppFirst, Inc.	Jun. 30, 2013 Technology Beyond.com, Inc	Jun. 30, 2013 Technology Bridgevine, Inc.	Jun. 30, 2013 Technology DriveFactor Inc.	Jun. 30, 2013 Technology Hoopla Software, Inc.	Jun. 30, 2013 Technology Lumesis, Inc.	Jun. 30, 2013 Technology MediaMath, Inc.	Jun. 30, 2013 Technology Pneuron, Inc.	Jun. 30, 2013 Technology Spongecell, Inc.	Jun. 30, 2013 Technology ThingWorx, Inc.
Schedule Of Equity Method Investments [Line Items]
Ownership interest under equity method, percentage	7.70%	27.60%	40.20%	49.20%		30.00%	34.50%	30.30%			24.60%	27.60%		35.00%	38.30%	22.50%	35.40%	25.30%	44.20%	22.20%	27.60%	23.10%	39.80%
Ownership interest under cost method, percentage					12.60%								7.40%
Ownership interest under fair value method, percentage									16.60%	[1]

[1] The Company's ownership interest in NuPathe was accounted for as available-for-sale securities following NuPathe’s completion of an initial public offering in August 2010. In October 2012, the Company participated in a private placement of NuPathe preferred stock units, and in conjunction with this financing, the Company placed two persons on NuPathe's board of directors. As a result, the Company determined that it exercised significant influence over NuPathe which made the equity method of accounting applicable to its ownership interests. Instead, the Company elected the fair value option beginning in October 2012. Prior to August 2010, the Company accounted for NuPathe under the equity method.

XML

Carrying Value and Fair Value of Certain Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Detail) (USD $) In Thousands, unless otherwise specified	Jun. 30, 2013	Dec. 31, 2012
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Cash held in escrow		$ 6,434
Restricted marketable securities	6	10
Fair Value, Measurements, Recurring | Carrying (Reported) Amount, Fair Value Disclosure
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Cash and cash equivalents	102,732	66,029
Cash held in escrow		6,434
Restricted marketable securities	6	10
Available-for-sale securities	18	58
Warrant participations	417	423
Total marketable securities, Fair Value Measurement	77,377	140,016
Fair Value, Measurements, Recurring | Fair Value Measurement | Level 1
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Cash and cash equivalents	102,732	66,029
Cash held in escrow		6,434
Restricted marketable securities	6	10
Available-for-sale securities	18	58
Warrant participations
Total marketable securities, Fair Value Measurement	77,377	140,016
Fair Value, Measurements, Recurring | Fair Value Measurement | Level 2
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Cash and cash equivalents
Cash held in escrow
Restricted marketable securities
Available-for-sale securities
Warrant participations
Total marketable securities, Fair Value Measurement
Fair Value, Measurements, Recurring | Fair Value Measurement | Level 3
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Cash and cash equivalents
Cash held in escrow
Restricted marketable securities
Available-for-sale securities
Warrant participations	417	423
Total marketable securities, Fair Value Measurement
NuPathe | Fair Value, Measurements, Recurring | Common Stock | Carrying (Reported) Amount, Fair Value Disclosure
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Ownership interest	15,791	8,897
NuPathe | Fair Value, Measurements, Recurring | Common Stock | Fair Value Measurement | Level 1
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Ownership interest	15,791	8,897
NuPathe | Fair Value, Measurements, Recurring | Common Stock | Fair Value Measurement | Level 2
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Ownership interest
NuPathe | Fair Value, Measurements, Recurring | Common Stock | Fair Value Measurement | Level 3
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Ownership interest
NuPathe | Fair Value, Measurements, Recurring | Preferred stock, warrants and options | Carrying (Reported) Amount, Fair Value Disclosure
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Ownership interest	3,572
NuPathe | Fair Value, Measurements, Recurring | Preferred stock, warrants and options | Fair Value Measurement | Level 1
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Ownership interest
NuPathe | Fair Value, Measurements, Recurring | Preferred stock, warrants and options | Fair Value Measurement | Level 2
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Ownership interest
NuPathe | Fair Value, Measurements, Recurring | Preferred stock, warrants and options | Fair Value Measurement | Level 3
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Ownership interest	3,572
NuPathe | Fair Value, Measurements, Recurring | Preferred Stock Warrants | Carrying (Reported) Amount, Fair Value Disclosure
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Ownership interest		12,075
NuPathe | Fair Value, Measurements, Recurring | Preferred Stock Warrants | Fair Value Measurement | Level 1
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Ownership interest
NuPathe | Fair Value, Measurements, Recurring | Preferred Stock Warrants | Fair Value Measurement | Level 2
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Ownership interest
NuPathe | Fair Value, Measurements, Recurring | Preferred Stock Warrants | Fair Value Measurement | Level 3
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Ownership interest		12,075
Commercial paper | Fair Value, Measurements, Recurring | Carrying (Reported) Amount, Fair Value Disclosure
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total marketable securities, Fair Value Measurement	19,237	50,932
Commercial paper | Fair Value, Measurements, Recurring | Fair Value Measurement | Level 1
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total marketable securities, Fair Value Measurement	19,237	50,932
Commercial paper | Fair Value, Measurements, Recurring | Fair Value Measurement | Level 2
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total marketable securities, Fair Value Measurement
Commercial paper | Fair Value, Measurements, Recurring | Fair Value Measurement | Level 3
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total marketable securities, Fair Value Measurement
U.S. Treasury Bills | Fair Value, Measurements, Recurring | Carrying (Reported) Amount, Fair Value Disclosure
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total marketable securities, Fair Value Measurement	18,180	21,352
U.S. Treasury Bills | Fair Value, Measurements, Recurring | Fair Value Measurement | Level 1
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total marketable securities, Fair Value Measurement	18,180	21,352
U.S. Treasury Bills | Fair Value, Measurements, Recurring | Fair Value Measurement | Level 2
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total marketable securities, Fair Value Measurement
U.S. Treasury Bills | Fair Value, Measurements, Recurring | Fair Value Measurement | Level 3
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total marketable securities, Fair Value Measurement
Government agency bonds | Fair Value, Measurements, Recurring | Carrying (Reported) Amount, Fair Value Disclosure
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total marketable securities, Fair Value Measurement	22,166	45,909
Government agency bonds | Fair Value, Measurements, Recurring | Fair Value Measurement | Level 1
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total marketable securities, Fair Value Measurement	22,166	45,909
Government agency bonds | Fair Value, Measurements, Recurring | Fair Value Measurement | Level 2
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total marketable securities, Fair Value Measurement
Government agency bonds | Fair Value, Measurements, Recurring | Fair Value Measurement | Level 3
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total marketable securities, Fair Value Measurement
Certificates of deposit | Fair Value, Measurements, Recurring | Carrying (Reported) Amount, Fair Value Disclosure
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total marketable securities, Fair Value Measurement	17,794	21,823
Certificates of deposit | Fair Value, Measurements, Recurring | Fair Value Measurement | Level 1
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total marketable securities, Fair Value Measurement	17,794	21,823
Certificates of deposit | Fair Value, Measurements, Recurring | Fair Value Measurement | Level 2
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total marketable securities, Fair Value Measurement
Certificates of deposit | Fair Value, Measurements, Recurring | Fair Value Measurement | Level 3
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total marketable securities, Fair Value Measurement

XML

Convertible Debentures and Credit Arrangements - Credit Arrangements - Additional Information (Detail) (Credit Arrangements, USD $) In Millions, unless otherwise specified	6 Months Ended
	Jun. 30, 2013
Debt Instrument [Line Items]
Maximum aggregate amount of revolving credit facility in the form of borrowings, guarantees and issuances of letters of credit (subject to a $20 million sublimit)	$ 50
Sublimit facility attached on revolving credit facility	20
Amount of depository, operating accounts, the lesser and investment and securities accounts required to be maintained at the lending bank	80
Percentage of depository, operating accounts, the lesser and investment and securities accounts required to be maintained at the lending bank	75.00%
Amount available for borrowing under revolving credit facility	43.7
After Amendment
Debt Instrument [Line Items]
Credit facility maturity date	Dec. 31, 2014
Landlord of CompuCom Systems
Debt Instrument [Line Items]
Letter of credit under the credit facility	$ 6.3
Letter of credit expiration date	Mar. 19, 2019

XML

Income Taxes - Additional Information (Detail) (USD $) In Thousands, unless otherwise specified	3 Months Ended		6 Months Ended
	Jun. 30, 2013	Jun. 30, 2012	Jun. 30, 2013	Jun. 30, 2012
Income Taxes [Line Items]
Income tax benefit (expense)	$ 0	$ 0	$ 0	$ 0

XML

CONSOLIDATED BALANCE SHEETS (Parenthetical) (USD $) In Thousands, except Per Share data, unless otherwise specified	Jun. 30, 2013	Dec. 31, 2012
Ownership interests in and advances, to partner companies and funds, fair value	$ 19,363	$ 20,972
Preferred stock, par value	$ 0.10	$ 0.10
Preferred stock, shares authorized	1,000	1,000
Common stock, par value	$ 0.10	$ 0.10
Common stock, shares authorized	83,333	83,333
Common stock, shares issued	20,977	20,968
Common stock, shares outstanding	20,977	20,968

XML

Income Taxes

6 Months Ended

Jun. 30, 2013

Income Taxes

7. Income Taxes

The Company’s consolidated income tax benefit (expense) was $0.0 million for the three and six months ended June30, 2013 and 2012. The Company has recorded a valuation allowance to reduce its net deferred tax asset to an amount that is more likely than not to be realized in future years. Accordingly, the tax benefit related to the net operating losses that would have been recognized in the three and six three months ended June30, 2013 and 2012 were offset by changes in the valuation allowance.

During the three and six months ended June30, 2013, the Company had no material changes in uncertain tax positions.

XML

CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (USD $) In Thousands, unless otherwise specified	3 Months Ended		6 Months Ended
	Jun. 30, 2013	Jun. 30, 2012	Jun. 30, 2013	Jun. 30, 2012
Net loss	$ (28,123)	$ (10,137)	$ (40,062)	$ (19,797)
Other comprehensive income (loss), before taxes:
Unrealized net gain (loss) on available-for-sale securities	(26)	734	(40)	5,800
Reclassification adjustment for other than temporary impairment of available-for-sale securities included in net loss	26	144	40	144
Total comprehensive loss	$ (28,123)	$ (9,259)	$ (40,062)	$ (13,853)

XML

CONSOLIDATED BALANCE SHEETS (USD $) In Thousands, unless otherwise specified	Jun. 30, 2013	Dec. 31, 2012
Current Assets:
Cash and cash equivalents	$ 102,732	$ 66,029
Cash held in escrow		6,434
Marketable securities	70,231	110,957
Restricted marketable securities	6	10
Prepaid expenses and other current assets	1,334	2,408
Total current assets	174,303	185,838
Property and equipment, net	164	193
Ownership interests in and advances to partner companies and funds (of which $19,363 and $20,972 are measured at fair value at June 30, 2013 and December 31, 2012, respectively)	143,100	148,639
Loan participations receivable	8,310	7,085
Available-for-sale securities	18	58
Long-term marketable securities	7,146	29,059
Other assets	3,077	3,272
Total Assets	336,118	374,144
Current Liabilities:
Convertible senior debentures-current	470
Accounts payable	203	610
Accrued compensation and benefits	3,634	4,050
Accrued expenses and other current liabilities	3,631	2,601
Total current liabilities	7,938	7,261
Other long-term liabilities	3,862	3,921
Convertible senior debentures-non-current	48,970	48,991
Total Liabilities	60,770	60,173
Commitments and contingencies
Equity:
Preferred stock, $0.10 par value; 1,000 shares authorized
Common stock, $0.10 par value; 83,333 shares authorized; 20,977 and 20,968 shares issued and outstanding at June 30, 2013 and December 31, 2012, respectively	2,098	2,097
Additional paid-in capital	817,384	815,946
Accumulated deficit	(544,134)	(504,072)
Total Equity	275,348	313,971
Total Liabilities and Equity	$ 336,118	$ 374,144

XML

Fair Value Measurements - Additional Information (Detail) (USD $)			3 Months Ended		1 Months Ended	3 Months Ended
	Jun. 30, 2013	Dec. 31, 2012	Jun. 30, 2013 PixelOptics, Inc.	Jun. 30, 2013 PixelOptics, Inc. Level 3	Feb. 28, 2013 NuPathe	Jun. 30, 2013 Penn Mezzanine
Schedule Of Available For Sale Securities [Line Items]
Marketable securities, current	$ 70,231,000	$ 110,957,000
Marketable securities, non current	7,146,000	29,059,000
Number of convertible preferred stock units					2,500
Number of common shares after conversion					2,500,000
Impairment charges			9,900,000			300,000
Ownership interest				$ 3,300,000

XML

Operating Segments (Tables)

6 Months Ended

Jun. 30, 2013

Active Partner Companies by Segment

The Company’s active partner companies by segment were as follows as of June30, 2013:

Healthcare
Partner Company	SafeguardPrimaryOwnership asofJune30,2013		AccountingMethod
AdvantEdge Healthcare Solutions, Inc.	40.2	%	Equity
Alverix, Inc.	49.2	%	Equity
Crescendo Bioscience, Inc.	12.6	%	Cost
Good Start Genetics, Inc.	30.0	%	Equity
Medivo, Inc.	34.5	%	Equity
NovaSom, Inc.	30.3	%	Equity
NuPathe, Inc.	16.6	%	Fairvalue(1)
PixelOptics, Inc.	24.6	%	Equity
Putney, Inc.	27.6	%	Equity
Sotera Wireless, Inc.	7.4	%	Cost

Technology
Partner Company	SafeguardPrimaryOwnership asofJune30,2013		AccountingMethod
AppFirst, Inc.	35.0	%	Equity
Beyond.com, Inc.	38.3	%	Equity
Bridgevine, Inc.	22.5	%	Equity
DriveFactor, Inc.	35.4	%	Equity
Hoopla Software, Inc.	25.3	%	Equity
Lumesis, Inc.	44.2	%	Equity
MediaMath, Inc.	22.2	%	Equity
Pneuron, Inc.	27.6	%	Equity
Spongecell, Inc.	23.1	%	Equity
ThingWorx, Inc.	39.8	%	Equity

(1) The Company's ownership interest in NuPathe was accounted for as available-for-sale securities following NuPathe’s completion of an initial public offering in August 2010. In October 2012, the Company participated in a private placement of NuPathe preferred stock units, and in conjunction with this financing, the Company placed two persons on NuPathe's board of directors. As a result, the Company determined that it exercised significant influence over NuPathe which madethe equity method of accounting applicable to its ownership interests. Instead, the Company elected the fair value option beginning in October 2012. Prior to August 2010, the Company accounted for NuPathe under the equity method.

Segment Data from Operations

	Three Months Ended June 30, 2013
	Healthcare			Technology			Penn Mezzanine			Total Segments				Other Items				Total
		(In thousands)
		(Unaudited)
Operating loss	$	-		$	-		$	(4	)	$	(4	)	$		(6,711	)	$		(6,715	)
Interest income		-			-			380			380				410				790
Equity loss		(14,850	)		(3,399	)		(94	)		(18,343	)			(57	)			(18,400	)
Net loss		(17,275	)		(3,399	)		(13	)		(20,687	)			(7,436	)			(28,123	)
Segment Assets:
June 30, 2013		75,154			61,266			13,186			149,606				186,512				336,118
December 31, 2012		83,500			58,753			12,153			154,406				219,738				374,144

	Three Months Ended June 30, 2012
	Healthcare			Technology			Penn Mezzanine			Total Segments			Other Items				Total
		(In thousands)
		(Unaudited)
Operating loss	$	-		$	-		$	(2	)	$	(2	)	$	(5,146	)	$		(5,148	)
Interest income		-			-			277			277			318				595
Equity loss		(8,820	)		(56	)		(69	)		(8,945	)		(2	)			(8,947	)
Net loss		(3,270	)		(56	)		(533	)		(3,859	)		(6,278	)			(10,137	)

	Six Months Ended June 30, 2013
	Healthcare			Technology			Penn Mezzanine			Total Segments			Other Items			Total
		(In thousands)
		(Unaudited)
Operating loss	$	-		$	-		$	(9	)	$	(9	)	$	(12,080	)	$	(12,089	)
Interest income		-			-			724			724			800			1,524
Equity (loss) income		(20,750	)		(4,500	)		(164	)		(25,414	)		27			(25,387	)
Net (loss) income		(22,340	)		(4,500	)		328			(26,512	)		(13,550	)		(40,062	)

	Six Months Ended June 30, 2012
	Healthcare			Technology			Penn Mezzanine			Total Segments				Other Items				Total
		(In thousands)
		(Unaudited)
Operating loss	$	-		$	-		$	(4	)	$	(4	)	$		(9,887	)	$		(9,891	)
Interest income		-			-			848			848				646				1,494
Equity loss		(15,159	)		(1,045	)		(188	)		(16,392	)			(3	)			(16,395	)
Net loss		(6,180	)		(1,045	)		(83	)		(7,308	)			(12,489	)			(19,797	)

XML

Commitments and Contingencies - Additional Information (Detail) (USD $)	1 Months Ended	6 Months Ended			3 Months Ended	6 Months Ended
	May 31, 2008	Jun. 30, 2013	Jun. 30, 2012	Dec. 31, 2012	Jun. 30, 2013 Employee Severance	Jun. 30, 2013 Letter of credit	Jun. 30, 2013 Property lease guarantee Laureate Pharma's	Jun. 30, 2013 Clawback Liability	Jun. 30, 2013 Accrued expenses and other current liabilities	Jun. 30, 2013 Accrued expenses and other current liabilities Clawback Liability	Jun. 30, 2013 Other long-term liabilities	Jun. 30, 2013 Other long-term liabilities Clawback Liability	Jun. 30, 2013 Private equity funds
Commitment Contingencies And Guarantees [Line Items]
Company outstanding guarantees		$ 3,800,000			$ 2,400,000	$ 6,300,000
Committed capital of private equity funds													100,000
Accrued expenses and other current liabilities								1,300,000
Accrued expenses and other current liabilities		3,631,000		2,601,000						1,000,000
Other long-term liabilities		3,862,000		3,921,000								300,000
Company's ownership in the funds								19.00%
Proceeds from sales of and distributions from companies and funds	6,400,000	1,403,000	11,061,000
Remaining lease payments							4,200,000
Guarantee lease expiration year of Laureate Pharma's		2016
Annual payments		650,000
Liability to former chairman and chief executive officer, current									800,000
Liability to former chairman and chief executive officer, non-current											2,800,000
Letter of credit expiration date						Mar. 19, 2019
Severance charge					$ 900,000

XML

Net Loss Per Share - Additional Information (Detail) (USD $) In Thousands, except Per Share data, unless otherwise specified	3 Months Ended		6 Months Ended
	Jun. 30, 2013	Jun. 30, 2012	Jun. 30, 2013	Jun. 30, 2012
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Shares of common stock at prices ranging, lower limit	$ 3.93	$ 3.93	$ 3.93	$ 3.93
Shares of common stock at prices ranging, upper limit	$ 18.80	$ 18.80	$ 18.80	$ 18.80
Stock Options
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Share of common stock excluded from diluted net loss per share calculation	3,300	3,200	3,300	3,200
Deferred stock units, performance-based stock units and restricted stock
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Share of common stock excluded from diluted net loss per share calculation	400	200	400	200
Convertible Senior Debentures due 2024
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Share of common stock excluded from diluted net loss per share calculation	10	10	10	10
Convertible Senior Debentures due 2014
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Share of common stock excluded from diluted net loss per share calculation	4	2,800	4	2,800
Convertible Senior Debentures due 2018
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Share of common stock excluded from diluted net loss per share calculation	3,000		3,000

XML

Stock-Based Compensation Expense (Detail) (USD $) In Thousands, unless otherwise specified	3 Months Ended		6 Months Ended
	Jun. 30, 2013	Jun. 30, 2012	Jun. 30, 2013	Jun. 30, 2012
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Stock-based compensation expense	$ 922	$ 846	$ 1,298	$ 1,229
General And Administrative Expenses
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Stock-based compensation expense	$ 922	$ 846	$ 1,298	$ 1,229

XML

Stock-Based Compensation - Additional Information (Detail) (USD $) In Millions, except Share data, unless otherwise specified	3 Months Ended		6 Months Ended		3 Months Ended		6 Months Ended		3 Months Ended		6 Months Ended					3 Months Ended		6 Months Ended
	Jun. 30, 2013 Market Based Awards	Jun. 30, 2012 Market Based Awards	Jun. 30, 2013 Market Based Awards	Jun. 30, 2012 Market Based Awards	Jun. 30, 2013 Performance Shares	Jun. 30, 2012 Performance Shares	Jun. 30, 2013 Performance Shares	Jun. 30, 2012 Performance Shares	Mar. 31, 2013 Service Based Award	Jun. 30, 2012 Service Based Award	Jun. 30, 2013 Service Based Award	Jun. 30, 2012 Service Based Award	Jun. 30, 2013 Deferred Stock Units	Jun. 30, 2012 Deferred Stock Units	Jun. 30, 2012 Unrestricted Shares	Jun. 30, 2013 Deferred stock units, performance-based stock units and restricted stock	Jun. 30, 2012 Deferred stock units, performance-based stock units and restricted stock	Jun. 30, 2013 Deferred stock units, performance-based stock units and restricted stock	Jun. 30, 2012 Deferred stock units, performance-based stock units and restricted stock
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Options vested			0	0
Stock-based compensation expense	$ 0.1	$ 0.1	$ 0.1	$ 0.2	$ 0.1	$ 0.1	$ 0.2	$ 0.1	$ 0.1	$ 0.3	$ 0.2	$ 0.4			$ 0.1	$ 0.6	$ 0.3	$ 0.7	$ 0.5
Options issued			0	0			0	0			28,000	43,000
Stock-based compensation, maximum number of unvested shares			956,000
Expiration period			8 years
Performance based maximum number of unvested shares							805,000
Expiration term											8 years
Vesting period											4 years
Deferred stock units issued to non-employee directors													44,000	22,000
Vesting term													Deferred stock units issued to directors in lieu of directors fees are 100% vested at the grant date; matching deferred stock units equal to 25% of directors’ fees deferred vest one year following the grant date or, if earlier, upon reaching age 65.
Percentage of shares vested in lieu of directors fees at the grant date													100.00%
Portion of Director fees matched to deferred stock units													25.00%
Vesting period of deferred stock													1 year
Minimum age required for meeting directors fees deferred vest criteria													65 years
Share based compensation arrangement by share based payment award equity instruments other than options issued in period															5,000

XML

Stock-Based Compensation

6 Months Ended

Jun. 30, 2013

Stock-Based Compensation

6. Stock-Based Compensation

Stock-based compensation expense was recognized in the Consolidated Statements of Operations as follows:

	ThreeMonthsEndedJune30,				SixMonthsEndedJune30,
	2013		2012		2013		2012
		(Inthousands)				(In thousands)
		(Unaudited)				(Unaudited)
General and administrative expense	$	922	$	846	$	1,298	$	1,229
	$	922	$	846	$	1,298	$	1,229

The fair value of the Company’s stock-based awards to employees was estimated at the date of grant using the Black-Scholes option-pricing model. The risk-free rate was based on the U.S. Treasury yield curve in effect at the end of the quarter in which the grant occurred. The expected term of stock options granted was estimated using the historical exercise behavior of employees. Expected volatility was based on historical volatility measured using weekly price observations of the Company’s common stock for a period equal to the stock option’s expected term.

At June30, 2013, the Company had outstanding options that vest based on three different types of vesting schedules:

1)market–based;

2)performance-based; and

3)service-based.

Market-based awards entitle participants to vest in a number of options determined by achievement by the Company of certain target market capitalization increases (measured by reference to stock price increases on a specified number of outstanding shares) over an eight-year period. The requisite service periods for the market-based awards are based on the Company’s estimate of the dates on which the market conditions will be met as determined using a Monte Carlo simulation model. Compensation expense is recognized over the requisite service periods using the straight-line method but is accelerated if market capitalization targets are achieved earlier than estimated. During the six months ended June30, 2013 and 2012, respectively, the Company did not issue any market-based option awards to employees. During the six months ended June30, 2013 and 2012, respectively, no options vested based on achievement of market capitalization targets. The Company recorded compensation expense related to market-based option awards of $0.1 million in both the three months ended June30, 2013 and 2012, and $0.1 million and $0.2 million for the six months ended June30, 2013 and 2012, respectively. Depending on the Company’s stock performance, the maximum number of unvested shares at June30, 2013 attainable under these grants was 956thousand shares.

Performance-based awards entitle participants to vest in a number of awards determined by achievement by the Company of target capital returns based on net cash proceeds received by the Company on the sale, merger or other exit transaction of certain identified partner companies. Vesting may occur, if at all, once per year. The requisite service periods for the performance-based awards are based on the Company’s estimate of when the performance conditions will be met. Compensation expense is recognized for performance-based awards for which the performance condition is considered probable of achievement. Compensation expense is recognized over the requisite service periods using the straight-line method but is accelerated if capital return targets are achieved earlier than estimated. During the six months ended June30, 2013 and 2012, respectively, the Company did not issue any performance-based awards to employees. During the six months ended June30, 2013 and 2012, respectively, no performance-based awards vested. The Company recorded compensation expense related to performance-based option awards of $0.1 million for both the three months ended June30, 2013 and 2012, and $0.2 million and $0.1 million for the six months ended June30, 2013 and 2012, respectively. The maximum number of unvested shares at June30, 2013 attainable under these option grants was 805thousand shares.

All other outstanding options are service-based awards that generally vest over four years after the date of grant and expire eight years after the date of grant. Compensation expense is recognized over the requisite service period using the straight-line method. The requisite service period for service-based awards is the period over which the award vests. During the six months ended June30, 2013 and 2012, respectively, the Company issued 28 thousand and 43thousand service-based option awards to employees. The Company recorded compensation expense related to service-based option awards of $0.1 million and $0.3 million for the three months ended June30, 2013 and 2012, and $0.2 million and $0.4 million for the six months ended June30, 2013 and 2012, respectively.

During the six months ended June30, 2013 and 2012, respectively, the Company issued 44 thousand and 22thousand deferred stock units to non-employee directors for annual service grants or fees earned during the preceding quarter. Deferred stock units issued to directors in lieu of directors fees are 100% vested at the grant date; matching deferred stock units equal to 25% of directors’ fees deferred vest one year following the grant date or, if earlier, upon reaching age 65. Deferred stock units are payable in stock on a one-for-one basis. Payments related to the deferred stock units are generally distributable following termination of employment or service, death or permanent disability.

Total compensation expense for deferred stock units, performance-based stock units and restricted stock was approximately $0.6 million and $0.3 million for the three months ended June30, 2013 and 2012, and $0.7 million and $0.5 million for the six months ended June30, 2013 and 2012, respectively. During the six months ended June30, 2012, the Company issued five thousand unrestricted shares to members of its advisory board, and recorded expense of $0.1 million related to these awards.

XML

Convertible Debentures and Credit Arrangements - Convertible Senior Debentures due 2024 - Additional Information (Detail) (Convertible Senior Debentures due 2024, USD $) In Millions, except Per Share data, unless otherwise specified	6 Months Ended
	Jun. 30, 2013	Dec. 31, 2004
Debt Instrument [Line Items]
Convertible senior debentures, convertible latest date	Mar. 14, 2024
Conversion price (in dollars per share)	$ 43.3044
Fair value of Debentures outstanding	$ 0.4
Aggregate face value of convertible senior debentures		$ 150.0
Credit facility maturity date	Mar. 15, 2024
Convertible senior debentures, interest payment description	Semi-annually
Percentage of face amount which is equal to repurchase price for providing optional conversion of debentures	100.00%
Description of conversion for convertible senior debentures	The remaining 2024 Debenture holders have the right to require the Company to repurchase the 2024 Debentures on March 20, 2014 or March 20, 2019 at a repurchase price equal to 100% of their face amount, plus accrued and unpaid interest. In limited circumstances, the Company has the right to redeem all or some of the 2024 Debentures.
Scenario 1
Debt Instrument [Line Items]
Convertible senior debentures, optional repurchase date	Mar. 20, 2014
Scenario 2
Debt Instrument [Line Items]
Convertible senior debentures, optional repurchase date	Mar. 20, 2019

XML

Active Partner Companies by Segment (Parenthetical) (Detail) (NuPathe)	Oct. 31, 2012 Person
NuPathe
Schedule Of Equity Method Investments [Line Items]
Number of Board of directors	2

XML

Operating Segments

6 Months Ended

Jun. 30, 2013

Operating Segments

9. Operating Segments

In the fourth quarter of 2012, the Company expanded its focus within the former Life Sciences segment to include companies in the HealthTech sector and renamed that segment “Healthcare.” The HealthTech sector had previously been included in the Company’s Technology segment. AdvantEdge Healthcare Solutions, a provider of physician billing and practice management services and software, which had previously been reported within the Technology segment, is now reported under the Healthcare segment. As a result of the change, the Company has restated its previously reported segment disclosure information, to include the results of AdvantEdge Healthcare Solutions within the Healthcare segment.

As of June30, 2013, the Company held interests in 20 non-consolidated partner companies which are included in the Healthcare and Technology segments. Included in the Penn Mezzanine segment are the Company’s interests in the Penn Mezzanine management company and general partner and the Company’s participations in mezzanine loans and equity interests initiated by Penn Mezzanine.

The Company’s active partner companies by segment were as follows as of June30, 2013:

Healthcare
Partner Company	SafeguardPrimaryOwnership asofJune30,2013		AccountingMethod
AdvantEdge Healthcare Solutions, Inc.	40.2	%	Equity
Alverix, Inc.	49.2	%	Equity
Crescendo Bioscience, Inc.	12.6	%	Cost
Good Start Genetics, Inc.	30.0	%	Equity
Medivo, Inc.	34.5	%	Equity
NovaSom, Inc.	30.3	%	Equity
NuPathe, Inc.	16.6	%	Fairvalue(1)
PixelOptics, Inc.	24.6	%	Equity
Putney, Inc.	27.6	%	Equity
Sotera Wireless, Inc.	7.4	%	Cost

Technology
Partner Company	SafeguardPrimaryOwnership asofJune30,2013		AccountingMethod
AppFirst, Inc.	35.0	%	Equity
Beyond.com, Inc.	38.3	%	Equity
Bridgevine, Inc.	22.5	%	Equity
DriveFactor, Inc.	35.4	%	Equity
Hoopla Software, Inc.	25.3	%	Equity
Lumesis, Inc.	44.2	%	Equity
MediaMath, Inc.	22.2	%	Equity
Pneuron, Inc.	27.6	%	Equity
Spongecell, Inc.	23.1	%	Equity
ThingWorx, Inc.	39.8	%	Equity

(1) The Company's ownership interest in NuPathe was accounted for as available-for-sale securities following NuPathe’s completion of an initial public offering in August 2010. In October 2012, the Company participated in a private placement of NuPathe preferred stock units, and in conjunction with this financing, the Company placed two persons on NuPathe's board of directors. As a result, the Company determined that it exercised significant influence over NuPathe which madethe equity method of accounting applicable to its ownership interests. Instead, the Company elected the fair value option beginning in October 2012. Prior to August 2010, the Company accounted for NuPathe under the equity method.

As of June30, 2013, in the Penn Mezzanine segment, the Company has a 36% ownership interest in the management company and general partner of Penn Mezzanine L.P. The Company accounts for its interest under the equity method.

Results of the Healthcare and Technology segments reflect the equity income (loss) of their respective equity method partner companies, other income (loss) associated with fair value method and cost method partner companies and the gains or losses on the sale of their respective partner companies. Results of the Penn Mezzanine segment includes interest, dividends and participation fees earned on the mezzanine interests in which the Company participates as well as equity income (loss) associated with the Company’s management company and general partner interest in the Penn Mezzanine platform.

Management evaluates the Healthcare and Technology segments’ performance based on net income (loss) which is based on the number of partner companies accounted for under the equity method, the Company’s voting ownership percentage in these partner companies and the net results of operations of these partner companies, any impairment charges or gain (loss) on the sale of equity and cost method partner companies.

Management evaluates the Penn Mezzanine segment performance based on the performance of the mezzanine interests in which the Company participates. This includes an evaluation of the current and future cash flows associated with interest and dividend payments as well as estimated losses based on evaluating known and inherent risks in the investments in which the Company participates.

Other Items include certain expenses which are not identifiable to the operations of the Company’s operating business segments. Other Items primarily consist of general and administrative expenses related to corporate operations, including employee compensation, insurance and professional fees, including legal and finance, interest income, interest expense and other income (loss) and equity income (loss) related to certain private equity fund ownership interests. Other Items also include income taxes, which are reviewed by management independent of segment results.

As of June30, 2013 and December31, 2012, all of the Company’s assets were located in the United States.

Segment assets in Other Items included primarily cash, cash equivalents, cash held in escrow, and marketable securities of $180.1 million and $212.5million, at June30, 2013 and December31, 2012, respectively.

	Three Months Ended June 30, 2013
	Healthcare			Technology			Penn Mezzanine			Total Segments				Other Items				Total
		(In thousands)
		(Unaudited)
Operating loss	$	-		$	-		$	(4	)	$	(4	)	$		(6,711	)	$		(6,715	)
Interest income		-			-			380			380				410				790
Equity loss		(14,850	)		(3,399	)		(94	)		(18,343	)			(57	)			(18,400	)
Net loss		(17,275	)		(3,399	)		(13	)		(20,687	)			(7,436	)			(28,123	)
Segment Assets:
June 30, 2013		75,154			61,266			13,186			149,606				186,512				336,118
December 31, 2012		83,500			58,753			12,153			154,406				219,738				374,144

	Three Months Ended June 30, 2012
	Healthcare			Technology			Penn Mezzanine			Total Segments			Other Items				Total
		(In thousands)
		(Unaudited)
Operating loss	$	-		$	-		$	(2	)	$	(2	)	$	(5,146	)	$		(5,148	)
Interest income		-			-			277			277			318				595
Equity loss		(8,820	)		(56	)		(69	)		(8,945	)		(2	)			(8,947	)
Net loss		(3,270	)		(56	)		(533	)		(3,859	)		(6,278	)			(10,137	)

	Six Months Ended June 30, 2013
	Healthcare			Technology			Penn Mezzanine			Total Segments			Other Items			Total
		(In thousands)
		(Unaudited)
Operating loss	$	-		$	-		$	(9	)	$	(9	)	$	(12,080	)	$	(12,089	)
Interest income		-			-			724			724			800			1,524
Equity (loss) income		(20,750	)		(4,500	)		(164	)		(25,414	)		27			(25,387	)
Net (loss) income		(22,340	)		(4,500	)		328			(26,512	)		(13,550	)		(40,062	)

	Six Months Ended June 30, 2012
	Healthcare			Technology			Penn Mezzanine			Total Segments				Other Items				Total
		(In thousands)
		(Unaudited)
Operating loss	$	-		$	-		$	(4	)	$	(4	)	$		(9,887	)	$		(9,891	)
Interest income		-			-			848			848				646				1,494
Equity loss		(15,159	)		(1,045	)		(188	)		(16,392	)			(3	)			(16,395	)
Net loss		(6,180	)		(1,045	)		(83	)		(7,308	)			(12,489	)			(19,797	)

XML

Convertible Debentures and Credit Arrangements

6 Months Ended

Jun. 30, 2013

Convertible Debentures and Credit Arrangements

5.Convertible Debentures and Credit Arrangements

The carrying values of the Company’s convertible senior debentures were as follows:

	June30,2013			December31,2012
		(In thousands)
		(Unaudited)
Convertible senior debentures due 2018	$	48,970		$	48,483
Convertible senior debentures due 2014		29			67
Convertible senior debentures due 2024		441			441
		49,440			48,991
Less: current portion		(470	)		-
Convertible senior debentures – non current	$	48,970		$	48,991

Convertible Senior Debentures due 2018

In November 2012, Safeguard issued $55.0 million principal amount of its 5.25% convertible senior debentures due 2018 (the “2018 Debentures”). Proceeds from the offering were used to repurchase substantially all of the Company’s then outstanding 10.125% convertible senior debentures due 2014 (the “2014 Debentures”). Interest on the 2018 Debentures is payable semi-annually on May15 and November15.

Holders of the 2018 Debentures may convert their notes prior to November15, 2017 at their option only under the following circumstances:

during any calendar quarter commencing after the calendar quarter ending on December31, 2012, if the last reported sale price of the common stock for at least 20 trading days during the period of 30 consecutive trading days ending on the last trading day of the immediately preceding calendar quarter is greater than or equal to 130% of the conversion price on each applicable trading day;

during the five business day period after any five consecutive trading day period in which the trading price per $1,000 principal amount of notes for each trading day of the measurement period was less than 98% of the product of the last reported sale price of our common stock and the conversion rate on such trading day;

if the notes have been called for redemption; or

upon the occurrence of specified corporate events.

On or after November15, 2017, until the close of business on the second business day immediately preceding the maturity date, holders may convert their notes at any time, regardless of whether any of the foregoing conditions has been met. Upon conversion, the Company will satisfy its conversion obligation by paying or delivering, as the case may be, cash, shares of common stock or a combination of cash and shares of our common stock, at the Company’s election.

The conversion rate of the 2018 Debentures is 55.17 shares of common stock per $1,000 principal amount of debentures, equivalent to a conversion price of approximately $18.13 per share of common stock. The closing price per share of the Company’s common stock at June30, 2013 was $16.05.

On or after November15, 2016, the Company may redeem for cash any of the 2018 Debentures if the last reported sale price of the Company’s common stock exceeds 140% of the conversion price for at least 20 trading days during the period of 30 consecutive trading days ending on the trading day before the date that notice of redemption is given, including the last trading day of such period. Upon any redemption of the 2018 Debentures, the Company will pay a redemption price of 100% of their principal amount, plus accrued and unpaid interest to, but excluding, the date of redemption, and additional interest, if any.

The 2018 Debenture holders have the right to require the Company to repurchase the 2018 Debentures if the Company undergoes a fundamental change, which includes the sale of all or substantially all of the Company’s common stock or assets; liquidation; dissolution; a greater than 50% change in control; the delisting of the Company’s common stock from the New York Stock Exchange or the NASDAQ Global Market (or any of their respective successors); or a substantial change in the composition of the Company’s board of directors as defined in the governing agreement. Holders may require that the Company repurchase for cash all or part of their 2018 Debentures at a fundamental change repurchase price equal to 100% of the principal amount of the debentures to be repurchased, plus accrued and unpaid interest to, but excluding, the fundamental change repurchase date.

Because the 2018 Debentures may be settled in cash or partially in cash upon conversion, the Company separately accounts for the liability and equity components of the 2018 Debentures. The carrying amount of the liability component was determined at the transaction date by measuring the fair value of a similar liability that does not have an associated equity component. The carrying amount of the equity component represented by the embedded conversion option was determined by deducting the fair value of the liability component from the initial proceeds of the 2018 Debentures as a whole. At June30, 2013, the fair value of the $55.0 million outstanding 2018 Debentures was approximately $60.5 million, based on the midpoint of the bid and ask prices as of such date. AtJune30, 2013, the carrying amount of the equity component was $6.4 million, the principal amount of the liability component was $55.0 million, the unamortized discount was $6.0 million and the net carrying value of the liability component was $49.0 million. The Company is amortizing the excess of the face value of the 2018 Debentures over their carrying value over their term as additional interest expense using the effective interest method and recorded $0.5 million for the six months ended June30, 2013. The effective interest rate on the 2018 Debentures is 8.7%.

Convertible Senior Debentures due 2024

In 2004, the Company issued an aggregate of $150.0 million in face value of convertible senior debentures with a stated maturity date of March15, 2024 (the “2024 Debentures”). At June30, 2013, the fair value of the $0.4 million outstanding 2024 Debentures approximated their carrying value, based on the midpoint of bid and ask prices as of such date. Interest on the 2024 Debentures is payable semi-annually. At the debenture holders’ option, the 2024 Debentures are convertible into the Company’s common stock through March14, 2024, subject to certain conditions. The adjusted conversion rate of the 2024 Debentures is $43.3044 of principal amount per share. The remaining 2024 Debenture holders have the right to require the Company to repurchase the 2024 Debentures on March20, 2014 or March20, 2019 at a repurchase price equal to 100% of their face amount, plus accrued and unpaid interest. In limited circumstances, the Company has the right to redeem all or some of the 2024 Debentures.

Convertible Senior Debentures due 2014

In March 2010, the Company issued an aggregate of $46.9 million of the 2014 Debentures. As noted above, in November 2012, the Company repurchased substantially all of the 2014 Debentures for $58.7 million plus accrued interest.

Credit Arrangements

The Company is party to a loan agreement with a commercial bank which provides it with a revolving credit facility in the maximum aggregate amount of $50 million in the form of borrowings, guarantees and issuances of letters of credit (subject to a $20 million sublimit). Actual availability under the credit facility is based on the amount of cash maintained at the bank as well as the value of the Company’s public and private partner company interests. This credit facility bears interest at the prime rate for outstanding borrowings, subject to an increase in certain circumstances. Other than for limited exceptions, the Company is required to maintain all of its depository and operating accounts and the lesser of $80 million or 75% of its investment and securities accounts at the bank. The credit facility, as amended December21, 2012, matures on December31, 2014. Under the credit facility, the Company provided a $6.3 million letter of credit expiring on March19, 2019 to the landlord of CompuCom Systems, Inc.’s Dallas headquarters which was required in connection with the sale of CompuCom Systems in 2004. Availability under the Company’s revolving credit facility at June30, 2013 was $43.7 million.

XML

CONSOLIDATED STATEMENT OF CHANGES IN EQUITY (USD $) In Thousands	Total	Accumulated Deficit	Common Stock	Additional Paid-in Capital
Balance at Dec. 31, 2012	$ 313,971	$ (504,072)	$ 2,097	$ 815,946
Balance (in shares) at Dec. 31, 2012			20,968
Net loss	(40,062)	(40,062)
Stock options exercised, net	92		1	91
Stock options exercised, net (in shares)			9
Issuance of restricted stock, net	49			49
Stock-based compensation expense	1,298			1,298
Balance at Jun. 30, 2013	$ 275,348	$ (544,134)	$ 2,098	$ 817,384
Balance (in shares) at Jun. 30, 2013			20,977

XML

Convertible Debentures and Credit Arrangements - Convertible Senior Debentures due 2018 - Additional Information (Detail) (USD $)	1 Months Ended	6 Months Ended
	Nov. 30, 2012	Jun. 30, 2013
Convertible Senior Debentures due 2018
Debt Instrument [Line Items]
Conversion rate of common stock		55.17
Principal amount of convertible debentures		$ 1,000
Conversion price (in dollars per share)		$ 18.13
Closing price for common stock		$ 16.05
Cash redemption description		On or after November 15, 2016, the Company may redeem for cash any of the 2018 Debentures if the last reported sale price of the Company’s common stock exceeds 140% of the conversion price for at least 20 trading days during the period of 30 consecutive trading days ending on the trading day before the date that notice of redemption is given, including the last trading day of such period. Upon any redemption of the 2018 Debentures, the Company will pay a redemption price of 100% of their principal amount, plus accrued and unpaid interest to, but excluding, the date of redemption, and additional interest, if any.
Debentures redemption price		100.00%
Sales price of common stock to conversion price		140.00%
Change in control due to debentures redemption		50.00%
Percentage of principal amount and accrued and unpaid interest for repurchase of debt		100.00%
Outstanding debentures		55,000,000
Fair value of Debentures outstanding		60,500,000
Gross carrying amount of equity component		6,400,000
Principal amount of liability component		55,000,000
Unamortized discount		6,000,000
Carrying value of liability component		49,000,000
Additional interest expenses		500,000
Interest rate on debentures	5.25%	8.70%
Convertible senior debentures, convertible latest date		Nov. 15, 2017
Number of days within 30 consecutive trading days in which the closing price of the entity's common stock exceeded the conversion price giving the holders of the debentures an option (in days)		20 days
Number of consecutive trading days during which the closing price of the entity's common stock exceeded the conversion price for at least 20 days giving the holders of the debentures an option (in days)		30 days
Number of days after five consecutive trading days in which the trading price per $1,000 principal amount was less than 98% of the product of the closing sale price per share of Company common stock multiplied by the conversion rate on each such trading day (in days)		5 days
Number of consecutive trading days during which the trading price per $1,000 principal amount for at least five days was less than 98% of the product of the closing sale price per share of Company common stock multiplied by the conversion rate on each such trading day (in days)		5 days
Closing price is percentage of conversion price		98.00%
Aggregate face value of convertible senior debentures	55,000,000
Convertible senior debentures, expiration year	2018
Convertible senior debentures, interest payment description		Interest on the 2018 Debentures is payable semi-annually on May 15 and November 15.
Convertible Senior Debentures due 2018 | Minimum
Debt Instrument [Line Items]
Percentage of the closing sales price of the entity's common stock that the conversion price exceeded giving the holders of the debentures an option (as a percent)		130.00%
Convertible Senior Debentures due 2014
Debt Instrument [Line Items]
Interest rate on debentures	10.125%
Aggregate face value of convertible senior debentures		$ 46,900,000
Convertible senior debentures, expiration year	2014

XML

Fair Value Measurements (Tables)

6 Months Ended

Jun. 30, 2013

Carrying Value and Fair Value of Certain Financial Assets and Liabilities Measured at Fair Value on Recurring Basis

The following table provides the carrying value and fair value of certain financial assets and liabilities of the Company measured at fair value on a recurring basis as of June30, 2013 and December31, 2012:

	Carrying Value		FairValueMeasurementatJune30,2013
			Level1		Level2			Level3
		(In thousands)
		(Unaudited)
Cash and cash equivalents	$	102,732	$	102,732		$	—		$	—
Cash held in escrow		—		—			—			—
Restricted marketable securities		6		6			—			—
Ownership interest in common stock of NuPathe		15,791		15,791			—			—
Ownership interest in warrants and options of NuPathe		3,572		—			—			3,572
Available-for-sale securities		18		18			—			—
Warrant participations		417		—			—			417
Marketable securities—held-to-maturity:
Commercial paper	$	19,237	$	19,237		$	—		$	—
U.S. Treasury Bills		18,180		18,180			—			—
Government agency bonds		22,166		22,166			—			—
Certificates of deposit		17,794		17,794			—			—
Total marketable securities…………………………………………………	$	77,377	$	77,377		$	—		$	—

	Carrying Value		Fair Value Measurement atDecember 31, 2012
			Level 1		Level 2			Level 3
		(In thousands)
		(Unaudited)
Cash and cash equivalents	$	66,029	$	66,029		$	—		$	—
Cash held in escrow		6,434		6,434			—			—
Restricted marketable securities		10		10			—			—
Ownership interest in common stock of NuPathe		8,897		8,897			—			—
Ownership interest in preferred stock, warrants and options of NuPathe		12,075		—			—			12,075
Available-for-sale securities		58		58			—			—
Warrant participations		423		—			—			423
Marketable securities—held-to-maturity:
Commercial paper	$	50,932	$	50,932		$	—		$	—
U.S. Treasury Bills		21,352		21,352			—			—
Government agency bonds		45,909		45,909			—			—
Certificates of deposit		21,823		21,823			—			—
Total marketable securities…………………………………………………	$	140,016	$	140,016		$	—		$	—

XML

Net Loss Per Share

6 Months Ended

Jun. 30, 2013

Net Loss Per Share

8. Net Loss Per Share

The calculations of net loss per share were as follows:

	ThreeMonthsEndedJune30,						SixMonthsEndedJune30,
	2013			2012				2013			2012
		(Inthousandsexceptpersharedata)
		(Unaudited)
Basic:
Net loss	$	(28,123	)	$	(10,137	)		$	(40,062	)	$	(19,797	)
Weighted average common shares outstanding		21,128			20,927				21,119			20,903
Net loss per share	$	(1.33	)	$	(0.48	)		$	(1.90	)	$	(0.95	)
Diluted:
Net loss	$	(28,123	)	$	(10,137	)		$	(40,062	)	$	(19,797	)
Weighted average common shares outstanding		21,128			20,927				21,119			20,903
Net loss per share	$	(1.33	)	$	(0.48	)		$	(1.90	)	$	(0.95	)

Basic and diluted average common shares outstanding for purposes of computing net loss per share includes outstanding common shares and vested deferred stock units (DSUs).

If a consolidated or equity method partner company has dilutive stock options, unvested restricted stock, DSUs or warrants, diluted net loss per share is computed by first deducting the income attributable to the potential exercise of the dilutive securities of the partner company from net loss. Any impact is shown as an adjustment to net loss for purposes of calculating diluted net loss per share.

The following potential shares of common stock and their effects on loss were excluded from the diluted net loss per share calculation because their effect would be anti-dilutive:

• For the three and six months ended June30, 2013 and 2012, options to purchase 3.3million and 3.2million shares of common stock, respectively, at prices ranging from $3.93 to $18.80 for both periods, were excluded from the calculations.
• For the three and six months ended June30, 2013 and 2012, unvested restricted stock units, performance stock units and DSUs convertible into 0.4million and 0.2million shares of stock, respectively, were excluded from the calculations.
• For the three and six monthsended June30, 2013 and 2012, 10thousand shares of common stock representing the effect of the assumed conversion of the 2024 Debentures, were excluded from the calculations.
• For the three and six months ended June30, 2013 and 2012, 4thousand and 2.8million shares of common stock, respectively, representing the effect of the assumed conversion of the 2014 Debentures, were excluded from the calculations.
• For the three and six months ended June30, 2013, 3.0million shares of common stock representing the effect of the assumed conversion of the 2018 Debentures, were excluded from the calculation.

XML

Net Loss Per Share (Tables)

6 Months Ended

Jun. 30, 2013

Calculations of Net Loss Per Share

The calculations of net loss per share were as follows:

	ThreeMonthsEndedJune30,						SixMonthsEndedJune30,
	2013			2012				2013			2012
		(Inthousandsexceptpersharedata)
		(Unaudited)
Basic:
Net loss	$	(28,123	)	$	(10,137	)		$	(40,062	)	$	(19,797	)
Weighted average common shares outstanding		21,128			20,927				21,119			20,903
Net loss per share	$	(1.33	)	$	(0.48	)		$	(1.90	)	$	(0.95	)
Diluted:
Net loss	$	(28,123	)	$	(10,137	)		$	(40,062	)	$	(19,797	)
Weighted average common shares outstanding		21,128			20,927				21,119			20,903
Net loss per share	$	(1.33	)	$	(0.48	)		$	(1.90	)	$	(0.95	)

XML

Convertible Debentures and Credit Arrangements (Tables)

6 Months Ended

Jun. 30, 2013

Convertible Senior Debentures

The carrying values of the Company’s convertible senior debentures were as follows:

	June30,2013			December31,2012
		(In thousands)
		(Unaudited)
Convertible senior debentures due 2018	$	48,970		$	48,483
Convertible senior debentures due 2014		29			67
Convertible senior debentures due 2024		441			441
		49,440			48,991
Less: current portion		(470	)		-
Convertible senior debentures – non current	$	48,970		$	48,991

XML

Document and Entity Information	6 Months Ended
	Jun. 30, 2013	Jul. 25, 2013
Document Information [Line Items]
Document Type	10-Q/A
Amendment Flag	true
Amendment Description	Safeguard Scientifics, Inc. (the Registrant) is filing this amendment (the Form 10-Q/A) to our Quarterly Report on Form 10-Q for the quarter ended June 30, 2013 (the Form 10-Q), filed with the U.S. Securities and Exchange Commission on July 26, 2013, solely to correct an error on the cover page. The cover page of the Form 10-Q incorrectly stated that the amount of the Registrant’s Common Stock outstanding as of July 25, 2013 was 26,976,963 shares. The cover page of this Form 10-Q/A correctly states that the number of shares of outstanding Common Stock of the Registrant on July 25, 2013 was 20,976,963. This Form 10-Q/A should be read in conjunction with the original Form 10-Q, which continues to be presented as of the date of the Form 10-Q. Except as specifically noted above, this Form 10-Q/A does not modify or update disclosures in the original Form 10-Q. Accordingly, this Form 10-Q/A does not reflect events occurring after the filing of the Form 10-Q or modify or update any related or other disclosures.
Document Period End Date	Jun. 30, 2013
Document Fiscal Year Focus	2013
Document Fiscal Period Focus	Q2
Trading Symbol	SFE
Entity Registrant Name	SAFEGUARD SCIENTIFICS INC
Entity Central Index Key	0000086115
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	No
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Filer Category	Accelerated Filer
Entity Common Stock, Shares Outstanding		20,976,963

XML

Stock-Based Compensation (Tables)

6 Months Ended

Jun. 30, 2013

Stock-Based Compensation Expense

Stock-based compensation expense was recognized in the Consolidated Statements of Operations as follows:

	ThreeMonthsEndedJune30,				SixMonthsEndedJune30,
	2013		2012		2013		2012
		(Inthousands)				(In thousands)
		(Unaudited)				(Unaudited)
General and administrative expense	$	922	$	846	$	1,298	$	1,229
	$	922	$	846	$	1,298	$	1,229